ACRUS broadens contraceptive spray strategy

Acrux (ASX: ACR), the Australian company with patient-preferred technology for delivering drugs across the skin, today announced that it has reached agreement with Population Council, Inc., to amend the Licence Agreement signed in February 2006.

Under the Licence Agreement, Acrux is developing a contraceptive spray, combining Acrux's patented MDTS spray delivery technology with Population Council's new generation contraceptive Nestorone. Established in 1952 and headquartered in New York, Population Council has a proven track record in the successful development of female contraceptive products.

Under the terms of the amendment, Acrux is no longer restricted to developing and commercialising only contraceptive sprays containing Nestorone. All other material terms of the Licence Agreement remain unchanged.

"This amendment has paved the way for Acrux to apply MDTS to a far wider range of contraceptive hormones, which in turn makes our technology more attractive to potential global partners," said Richard Treagus, Acrux CEO.

Following the successful completion of Phase 1 clinical trials with Nestorone MDTS, Acrux has moved quickly to start formulation development of additional contraceptive spray products.

"The global market for hormonal contraceptives approximates US$6.5 billion per annum. With the MDTS technology applicable to a range of contraceptive hormones, it was important to ensure that we were in the strongest possible position to fully exploit the value of our technology in this market", Treagus added.

MDTS has a number of advantages over existing methods of contraceptive delivery systems, such as pills and patches. At launch, the contraceptive MDTS will be the first transdermal contraceptive spray in the market, and it has the potential to become the contraceptive of choice for many women.


Contact: Richard Treagus
Research Australia

Page: 1

Related biology news :

1. Species thrive when sexual dimorphism broadens their niches
2. Implanon, Norplant and Jadelle are all effective contraceptives -- but side effects vary
3. New research finds that a natural family planning method is as effective as the contraceptive pill
4. Lack of GBA2: A contraceptive for male mice
5. Male contraceptive study expands to 4 US cities
6. New male contraceptive targets sperm, not hormones
7. New male contraceptive clears hurdle
8. Of mice and mens (and womens) contraceptives
9. Global study concludes attack rate of flu in kids is 55 percent lower with nasal spray vaccine
10. Harvard team creates spray drying technique for TB vaccine
11. Flu shot effective against drifted influenza, nasal spray vaccine less so

Post Your Comments:

(Date:7/18/2020)... ... , ... Commercial launch readiness is a critical stage in a product life ... vaccine, the global economic downturn will only increase price pressures overall for the industry. ... full value from every product launch is critical. However, history shows that only a ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... detailing the use of its revolutionary NEXTGENPCR endpoint thermocycler to test for ... minutes. The article, titled "Ultra-fast one-step RT-PCR protocol for the detection of ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC , ... that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) ... with severe COVID-19. This is the first study of an XPO1 inhibitor in ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON Manufacturing, the ... new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes at a ... fast track capacity to provide patients with urgently needed vaccines and other lifesaving ...
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® Respiratory ... 16 countries, has reached its 20th anniversary of worldwide use. Introduced in the ... top universities including University of Pennsylvania, University of Michigan, University of Maryland, University ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... ... solutions to aid in the early detection and prevention of high-burden diseases, and ... enable US-based hospitals and healthcare organizations to utilize existing data in order to ...
(Date:7/10/2020)... , ... July 09, 2020 , ... ... cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., as ... oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson serves ...
Breaking Biology Technology:
Cached News: